Alzamend Neuro, Inc.

Listed Company

ALZNCIK 0001677077NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Apr 30

Period

FY 2025

Revenue

—

Net Income

$-4.51M

Total Assets

$4.60M

Equity

$3.97M

Shares Out

3.80M

Op. Cash Flow

$-6.57M

Business

Alzamend Neuro, Inc. develops and commercializes therapeutics aimed at treating Alzheimer’s disease, bipolar disorder, major depressive disorder and PTSD. Its main product candidates include AL001, a lithium-based formulation intended to increase brain lithium levels, and ALZN002, a biologic-focused candidate for Alzheimer’s, along with exploration of additional delivery methods. The company operates through clinical development and research collaborations, engaging CROs and academic partners for Phase trials and pipeline advancement. It targets regulatory approval and commercialization via FDA pathways and strategic partnerships with biopharmaceutical companies and distributors rather than direct retail sales.

Summary from filing dated 2025-07-22

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-04-30	FY 2024 2024-04-30	FY 2023 2023-04-30	FY 2022 2022-04-30	FY 2021 2021-04-30
Research and development	1	6	7	5	1
General and administrative	3	3	7	7	4
Total operating expenses	4	10	15	—	—
Loss from operations	−4	−10	−15	−12	−5
Interest expense	−18,029	−10,101	−7,701	−46,524	−142,421
Total other expense, net	−18,029	−10,101	−7,701	−42,524	−94,679
NET LOSS	−5	−10	−15	−12	−5
Dividend on preferred shares	−117,022	—	—	—	—
Deemed dividend on warrant modification issued with preferred	−473,209	—	—	—	—
NET LOSS ATTRIBUTED TO COMMON SHARES	−5	−10	—	—	—
Basic net loss per common share	−11.32	−132.33	−22.89	−0.14	—
Diluted net loss per common share	−11.32	−132.33	−22.89	−0.14	—
Basic weighted average common shares outstanding	450,799	74,174	650,126	89	73
Diluted weighted average common shares outstanding	450,799	74,174	650,126	89	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-04-30	FY 2024 2024-04-30	FY 2023 2023-04-30	FY 2022 2022-04-30	FY 2021 2021-04-30
Cash	4	376,048	5	14	2
Prepaid expenses and other current assets	228,719	79,194	447,589	349,723	983,320
TOTAL CURRENT ASSETS	4	455,242	6	14	3
Property and equipment, net	425,606	176,346	79,843	102,909	—
TOTAL ASSETS	5	631,588	6	15	3
Accounts payable and accrued liabilities	634,761	3	—	—	—
Note payable	—	300,714	—	—	—
TOTAL LIABILITIES, ALL CURRENT	634,761	3	3	1	899,643
Common stock, $0.0001 par value: 300,000,000 shares authorized; 778,733 and 76,444 issued and outstanding as of April 30, 2025 and 2024, respectively	78	8	65	9,548	6,743
Additional paid-in capital	63	51	62	57	34
Accumulated deficit	−59	−54	−44	−29	−17
TOTAL STOCKHOLDERS EQUITY (DEFICIT)	4	−3	3	13	2
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT)	5	631,588	6	15	3

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-04-30	FY 2024 2024-04-30	FY 2023 2023-04-30	FY 2022 2022-04-30	FY 2021 2021-04-30
Depreciation expense	50,740	50,740	23,066	3,549	—
Interest expense - debt discount	9,286	714	—	12,770	124,046
Stock-based compensation to employees and consultants	325,108	955,633	4	4	2
Prepaid expenses and other current assets	−149,525	368,395	−97,866	633,597	260,791
Prepaid expenses related party	—	247,334	739,918	—	—
Accounts payable and accrued liabilities	−2	54,937	2	—	—
Net cash used in operating activities	−7	−8	−9	−7	−3
Purchase of equipment	−300,000	−147,243	—	−106,458	—
Net cash used in investing activities	−300,000	−147,243	—	−106,458	100,915
Net proceeds from the issuance of common stock, net	3	1	—	6	2
Net proceeds from the issuance of preferred stock, net	8	—	—	—	—
Proceeds from stock option exercise	600	—	200	2,200	—
Proceeds from the issuance of note payable	—	300,000	—	—	—
Net proceeds from the issuance of preferred stock - related party	—	2	—	—	—
Net cash provided by financing activities	10	4	200	19	4
Net increase (decrease) in cash	4	−5	−9	12	—
Conversion of Series A convertible preferred stock to common stock	7	—	—	—	—
Conversion of Series C convertible preferred stock to common stock	239,712	—	—	—	—
Fair value of warrants issued in connection with Series A convertible preferred stock	2	—	—	—	—
Conversion of note payable and accrued interest into Series A convertible preferred stock	311,356	—	—	—	—
Exchange of Series A convertible preferred stock into Series C convertible preferred stock	977,511	—	—	—	—
Return of common stock for note receivable - related party	—	−15	—	—	—
Debt discount from issuance of note payable	—	10,000	—	—	—
Fair value of warrants issued with preferred stock	577,073	—	—	—	—
Fair value of warrants issued for related party payable	—	2	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro